AUS 2 7 2002

PTO/SB/30 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE decition Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

REQUEST

CONTINUED EXAMINATION (RCE) TRANSMITTAL

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995.

See The American Inventors Protection Act of 1999 (AIPA).

Application Number	10/050,347		5
Filing Date	January 15, 2002	8/2 6/	0
First Named Inventor	Gurtej Sandhu S.	Moc.	از
Group Art Unit	2813		
Examiner Name	Schillinger, L.		
Attorney Docket Number	MI22-1897		

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application. NOTE: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Final Rule, 65 Fed. Reg. 50092 (Aug. 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE practice.				
	N			
1. Submission required under 37 C.F.R. § 1.114	28 A 70			
a. Previously submitted i. Consider the amendment(s)/reply under 37 C.F.R. § 1.116 p. (Any unentered amendment(s) referred to above will be entered).	A 0 1			
ii. Consider the arguments in the Appeal Brief or Reply Brief p	reviously filed on			
iii.	RC 82 D			
b. 🗴 Enclosed	DO2			
i. x Amendment/Reply	-			
ii. Affidavit(s)/Declaration(s)				
iii. $\boxed{ exttt{X}}$ Information Disclosure Statement (IDS) w/PT0-1449 and copies of cited references .				
iv. X Other Return receipt postcard				
2. Miscellaneous				
	ata tara tara 07. 0.5.D. 0.4.400/a) fara			
a. Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for				
a period of months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required)				
b. Other				
3. Fees The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.				
a. X The Director is hereby authorized to charge the following fees, or credit any overpayments, to				
i. RCE fee required under 37 C.F.R. § 1.17(e) 08/30/2002 AWDNDAF1 00000102 10050347				
ii. Extension of time fee (37 C.F.R. §§ 1.136 and 1.17) 01 FC:179	740.00 OP			
C. Payment by credit card (Form PTO-2038 enclosed)				
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED				
Name (Print /Type) Jennifer J. Taylor, Ph.D. Regis	stration No. (Attorney/Agent) 48,711			
Signature ilem mides / landa Date	August 26,2002			
Melynyn I Tourion Butt	ITMINUS ON OFFICE :			
/ CERTIFICATE OF MAILING OR TRANSMISSION				
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an				
envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark				
Office on: EV 1 8 2 6 6 4 3 6 4				
Name (Print/Type)	<u> </u>			
Signature Date	6			
Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending	upon the needs of the individual case. Any comments on the			

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time—you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Assistant Commissioner for Patents, Box RCE, Washington, DC 20231.